
Sol-Gel Technologies (SLGL) Stock Forecast & Price Target
Sol-Gel Technologies (SLGL) Analyst Ratings
Bulls say
Sol-Gel Technologies Ltd has seen a significant upward revision in its financial projections, with an increase in peak annual sales per patient from $150K to $250K, indicating strong market potential for its products. The anticipated approval of SGT-610, which aims to prevent new basal cell carcinoma lesions in Gorlin syndrome patients, could generate annual peak revenues exceeding $300 million, further enhancing the company's growth outlook. Additionally, the potential for self-commercialization is highlighted by the manageable size of the Gorlin syndrome market, estimated at around 11,000 patients in the U.S., providing a favorable landscape for Sol-Gel's product offerings.
Bears say
Sol-Gel Technologies Ltd faces several significant risks that contribute to a negative outlook on its stock. The pivotal trial for SGT-610 in Gorlin syndrome may fail to generate positive results, which could hinder regulatory approval and further development. Additionally, setbacks in other programs, such as the discontinued SGT-210, combined with the potential for medium- to long-term dilution risk after a recent reverse stock split, undermine investor confidence and overall financial stability.
This aggregate rating is based on analysts' research of Sol-Gel Technologies and is not a guaranteed prediction by Public.com or investment advice.
Sol-Gel Technologies (SLGL) Analyst Forecast & Price Prediction
Start investing in Sol-Gel Technologies (SLGL)
Order type
Buy in
Order amount
Est. shares
0 shares